Eckert & Ziegler to join Chinese-German pharma development joint venture
Eckert & Ziegler AG by its subsidiary Eckert & Ziegler Radiopharma GmbH will acquire a minority interest in OctreoPharm Sciences GmbH, a company specialized in radiopharmaceuticals for nuclear medicine. OctreoPharm Sciences focuses on the clinical development of new types of radiopharmaceuticals for diagnostics and treatment in the field of oncology.
OctreoPharm Sciences has various peptides currently in pre-clinical development as a potential solution for the detection of neuroendocrine tumors using positron emission tomography (PET). Depending on the radionuclide it is coupled with, it could be used both in diagnosing (gallium-68) and treating (yttrium-90) such tumors. Clinical testing on humans (phase I) is slated to begin towards the end of next year.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.